Paradigm Capital Management Inc. NY continued to hold its stake in shares of Nu Skin Enterprises, Inc. (NYSE:NUS) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,000 shares of the company’s stock at the end of the first quarter. Paradigm Capital Management Inc. NY’s holdings in Nu Skin Enterprises were worth $278,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. AQR Capital Management LLC boosted its stake in shares of Nu Skin Enterprises by 28.8% in the fourth quarter. AQR Capital Management LLC now owns 1,664,001 shares of the company’s stock worth $79,506,000 after buying an additional 372,166 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Nu Skin Enterprises by 4.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 947,226 shares of the company’s stock worth $45,260,000 after buying an additional 39,926 shares during the period. State Street Corp boosted its stake in shares of Nu Skin Enterprises by 2.4% in the fourth quarter. State Street Corp now owns 802,056 shares of the company’s stock worth $38,321,000 after buying an additional 18,471 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Nu Skin Enterprises by 91.5% in the first quarter. Bank of New York Mellon Corp now owns 724,762 shares of the company’s stock worth $40,253,000 after buying an additional 346,236 shares during the period. Finally, Norges Bank purchased a new stake in shares of Nu Skin Enterprises during the fourth quarter worth about $27,260,000. 78.88% of the stock is owned by hedge funds and other institutional investors.
Nu Skin Enterprises, Inc. (NYSE:NUS) traded up 0.63% during mid-day trading on Friday, reaching $55.90. The company’s stock had a trading volume of 407,487 shares. Nu Skin Enterprises, Inc. has a 52 week low of $38.19 and a 52 week high of $66.04. The firm has a 50-day moving average of $55.59 and a 200-day moving average of $52.72. The stock has a market capitalization of $2.95 billion, a price-to-earnings ratio of 18.55 and a beta of 1.66.
Nu Skin Enterprises (NYSE:NUS) last posted its earnings results on Wednesday, May 3rd. The company reported $0.51 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.01. The company had revenue of $499.10 million during the quarter, compared to analyst estimates of $493.65 million. Nu Skin Enterprises had a return on equity of 20.06% and a net margin of 6.26%. The business’s revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.42 earnings per share. On average, equities research analysts expect that Nu Skin Enterprises, Inc. will post $3.12 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 14th. Stockholders of record on Friday, May 26th will be given a dividend of $0.36 per share. The ex-dividend date of this dividend is Wednesday, May 24th. This represents a $1.44 annualized dividend and a dividend yield of 2.59%. Nu Skin Enterprises’s dividend payout ratio is presently 57.96%.
A number of analysts recently issued reports on NUS shares. Zacks Investment Research cut Nu Skin Enterprises from a “buy” rating to a “hold” rating in a research report on Saturday, May 6th. Sidoti cut Nu Skin Enterprises from a “buy” rating to a “neutral” rating and set a $59.00 price objective for the company. in a research report on Wednesday, April 26th. Jefferies Group LLC set a $52.00 price objective on Nu Skin Enterprises and gave the stock a “hold” rating in a research report on Friday, February 17th. Deutsche Bank AG reaffirmed a “buy” rating and set a $63.00 price objective on shares of Nu Skin Enterprises in a research report on Sunday, February 19th. Finally, Pivotal Research reaffirmed a “buy” rating and set a $65.00 price objective on shares of Nu Skin Enterprises in a research report on Thursday, May 4th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $59.00.
In other news, General Counsel D Matthew Dorny sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $55.30, for a total transaction of $442,400.00. Following the completion of the transaction, the general counsel now directly owns 53,730 shares in the company, valued at $2,971,269. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 32,000 shares of company stock valued at $1,708,960. Insiders own 4.60% of the company’s stock.
Nu Skin Enterprises Company Profile
Nu Skin Enterprises, Inc is a direct selling company that develops and distributes personal care products and nutritional supplements, and a range of other products and services. The Company offers anti-aging personal care products and nutritional supplements under its Nu Skin and Pharmanex brands. The Nu Skin brand offers a range of products, including ageLOC Me customized skin care system, ageLOC Spa systems and ageLOC Transformation anti-aging skin care system.
Want to see what other hedge funds are holding NUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nu Skin Enterprises, Inc. (NYSE:NUS).
Receive News & Ratings for Nu Skin Enterprises Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises Inc. and related companies with MarketBeat.com's FREE daily email newsletter.